Is SNY a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

3,964 people get SNY articles and Market Currents by email alert.

Get email alerts on SNY »

FOCUS | PRO | RELATED | TRANSCRIPTS | NEWS & PR

Aubagio EU Backing Comes With Generic Worries
EP Vantage • Mon, Mar 25
After The Twists And Turns, Sanofi Still A Value
Stephen Simpson • Tue, Feb 12 • 7 Comments
Sanofi Misses Earnings But Steps In Right Direction
WM Analyst • Thu, Feb 7 • 3 Comments
GCVRZ: A Potential 16 Bagger Worth The Risk
Chris DeMuth Jr. • Mon, Jan 7 • 179 Comments
Beat Patent Cliffs: Buy Sanofi Now
Stock Croc • Thu, Nov 8, 2012 • 4 Comments
New Reasons To Be Bullish On Sanofi
Trading Maven • Tue, Nov 6, 2012
Why Does Sanofi Want To Sublicense Prednisporin?
Jorge Aura • Wed, Oct 31, 2012 • 5 Comments
Unique Approach Gives Sanofi An Edge
ValueMax • Tue, Oct 16, 2012 • 1 Comment
2 Healthcare Stocks To Watch In The Vaccine Market
IncomeHunter • Fri, Sep 28, 2012 • 2 Comments
Sanofi: A Long-Term Winner On These FDA Approvals
ValueMax • Wed, Sep 19, 2012 • 3 Comments
Sanofi Challenges Novartis For Multiple Sclerosis Market Share
Todd Campbell • Thu, Sep 13, 2012
Sanofi: Overvalued Or Overlooked?
Mel Daris • Tue, Sep 11, 2012 • 2 Comments
Is Sanofi The Best Pharma Stock To Buy?
Qineqt • Fri, Sep 7, 2012 • 8 Comments
Sanofi Looks Overvalued At $41
All American Investor • Thu, Aug 30, 2012 • 5 Comments
Sanofi Still Surprising And Surpassing
Stephen Simpson • Thu, Jul 26, 2012 • 5 Comments
Sanofi: Don't Ignore This Powerhouse
IncomeHunter • Sun, Jul 15, 2012 • 5 Comments
Sanofi: A European Stock That Offers A Prescription For Profit
GreensKeeper • Thu, Jun 28, 2012 • 2 Comments
New Drug Could Be Game Changer For Sanofi
Investment Underground • Thu, May 31, 2012 • 3 Comments
Sanofi: Kiss This Stock Goodbye
Mel Daris • Mon, May 21, 2012 • 3 Comments
4 New Reasons To Be Bullish On Sanofi Now
Mel Daris • Sun, May 13, 2012 • 6 Comments

After The Twists And Turns, Sanofi Still A Value
Stephen Simpson • Tue, Feb 12 • 7 Comments
GCVRZ: A Potential 16 Bagger Worth The Risk
Chris DeMuth Jr. • Mon, Jan 7 • 179 Comments

CryoPort's Game-Changer In Frozen Biological Shipping
Brian Marckx • Tue, Jun 18
Near A 52-Week Low, Is OncoGenex Pharmaceuticals A Buy?
C.R. Jackson • Thu, Jun 13
KaloBios: An Undervalued Pharmaceutical Company With Remarkable Pipeline
Biomed Group • Thu, Jun 13
Novartis: 5-Year Revenue Outlook
Bio Vantage • Thu, Jun 13 • 6 Comments
Unilife: Is 2013 The Tipping Point For This Pharma Stock?
Fusion Research • Thu, Jun 6 • 26 Comments
Solid Showing At WCN Conference For Keryx: Catalysts Still To Come
PropThink • Tue, Jun 4
Wall Street Breakfast: Must-Know News
Wall Street Breakfast • Mon, Jun 3 • 57 Comments
Johnson & Johnson - Avoid This Safety Stock
The Ethical Investor • Sun, Jun 2 • 31 Comments
Clearing The Air On The Sanofi-Regeneron Asthma Drug Trial
Alan Kotok • Tue, May 28
Yields From 3-11%: Intro To International Investing For Individual Investors
Mike the PhD • Thu, May 23 • 9 Comments
Will Influenza A H7N9 Generate Opportunities For Pharma?
Jean-Christophe Larsimont • Tue, May 21 • 6 Comments
Catalyst Pharmaceutical's CPP-115 May Be Big Pipeline In Just One Little Pill
Michael_Anderson • Mon, May 20 • 3 Comments
Complete Warren Buffett And Berkshire Hathaway 1st Quarter Portfolio Update
Profit Fan • Thu, May 16 • 10 Comments
Why Warren Buffett Sees Opportunity In Europe
Gary Bourgeault • Thu, May 16 • 4 Comments
Tracking Warren Buffett's Berkshire Hathaway Portfolio - Q1 2013 Update
John Vincent • Thu, May 16 • 3 Comments
LabStyle Innovations - Glucose Monitoring For The Mobile Age
Jason Napodano • Wed, May 15 • 13 Comments
10 Hot Healthcare Dogs Probe 6% To 38.2% Gains In April
Fredrik Arnold • Mon, May 13 • 2 Comments
Is Regeneron A Value Pick In The Pharma Sector?
Emerging Equities • Mon, May 13 • 3 Comments
3 Bio Companies Facing The Patent Cliff
Emerging Equities • Tue, May 7 • 1 Comment
Regeneron: Solid Q1 Creates Platform For Further Upside
PropThink • Tue, May 7

Sanofi Management Discusses Q1 2013 Results - Earnings Call Transcript
Thu, May 2
Sanofi's Management Presents at Barclays Global Healthcare Conference (Transcript)
Wed, Mar 13
Sanofi's CEO Discusses Q4 2012 Results - Earnings Call Transcript
Thu, Feb 7
Sanofi Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Oct 25, 2012 • 1 Comment
Sanofi Management Discusses Q2 2012 Results - Earnings Call Transcript
Thu, Jul 26, 2012
Sanofi-Aventis's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Fri, Apr 27, 2012
sanofi-aventis' Management Host IR Thematic Call on Multiple Sclerosis (Transcript)
Wed, Apr 25, 2012
sanofi-aventis' Management Presents at Credit Suisse Healthcare Conference (Transcript)
Fri, Mar 16, 2012
Sanofi's Management Presents at Cowen Group Health Care Conference (Transcript)
Tue, Mar 13, 2012
Sanofi's CEO to Present at JPMorgan Global Healthcare Conference (Transcript)
Sun, Mar 11, 2012
Sanofi's CEO Discusses Q4 2011 Results - Earnings Call Transcript
Wed, Feb 8, 2012
Sanofi's CEO Discusses Q3 2011 Results - Earnings Call Transcript
Sat, Nov 5, 2011
sanofi-aventis CEO Discusses Q2 2011 Results - Earnings Call Transcript
Thu, Jul 28, 2011
Sanofi-Aventis CEO Discusses Q1 2011 Results - Earnings Call Transcript
Thu, Apr 28, 2011
Sanofi-Aventis CEO Discusses Q4 2010 Results - Earnings Call Transcript
Wed, Feb 9, 2011
Genzyme Corporation CEO Discusses Q3 2010 Earnings - Call Transcript
Wed, Oct 20, 2010
Genzyme Corporation Q2 2010 Earnings Call Transcript
Wed, Jul 21, 2010
Genzyme Corporation Q1 2010 Earnings Call Transcript
Wed, Apr 21, 2010
Genzyme Corporation Q4 2009 Earnings Call Transcript
Wed, Feb 17, 2010
Sanofi-Aventis Q4 2009 Earnings Call Transcript
Thu, Feb 11, 2010

Stocks to Shrug Off Blood-Pressure Drug Dispute

at CNBC.com (May 31, 2013)
Europe Markets: European stocks slump as OECD cuts growth outlook

at MarketWatch.com (May 29, 2013)
Europe Markets: Europe stocks end higher after U.S. data

at MarketWatch.com (May 9, 2013)
Fear on the Floor Ahead of Jobs Report

at CNBC.com (May 2, 2013)
Futures Gain After Jobless Claims, ECB Rate Cut

at CNBC.com (May 2, 2013)
Europe Markets: Europe stocks end lower but Germany’s DAX gains

at MarketWatch.com (Apr 30, 2013)
Europe Markets: Italy leads European stock-market gains

at MarketWatch.com (Apr 29, 2013)
Fed May Provide a Safety Net for the Market

at CNBC.com (Apr 26, 2013)
Europe Markets: Europe stocks slide after China GDP; miners sink

at MarketWatch.com (Apr 15, 2013)
Bird Flu Returns, but China's Better Prepared: CEO

at CNBC.com (Apr 11, 2013)
Europe Markets: Europe stocks rally; Vodafone fuels M&A optimism

at MarketWatch.com (Apr 2, 2013)
Pro's Best Buys in Health Care

at CNBC.com (Mar 26, 2013)
Europe Markets: European stocks edge up as U.S. data claim focus

at MarketWatch.com (Mar 26, 2013)
Health-care Stocks: Osiris keeps losses down, investors reward shares

at MarketWatch.com (Mar 6, 2013)
Europe Markets: Europe stocks drop with China, sequester in focus

at MarketWatch.com (Mar 4, 2013)
Europe Markets: Europe stocks rally as German ZEW index posts rise

at MarketWatch.com (Feb 19, 2013)
Health-care Stocks: Novo Nordisk shares plunge on FDA rejection

at MarketWatch.com (Feb 11, 2013)
Midday Movers: REGN, FOSL & More

at CNBC.com (Feb 11, 2013)
Europe Markets: Novo Nordisk leads Europe lower after FDA news

at MarketWatch.com (Feb 11, 2013)
Early Movers: DELL, GOOG, SNY & More

at CNBC.com (Feb 11, 2013)

SNY vs. ETF Alternatives

Company Description

We are a global biotechnology company dedicated to making a major impact on the lives of people with serious diseases. Our broad product and service portfolio is focused on rare genetic disease disorders, renal disease, orthopaedics, cancer, transplant and immune disease, and diagnostic and... More

Sector: Healthcare

Industry: Drug Manufacturers - Major

Country: France

All
| Earnings
| Dividends
| M&A
| On the move

Monday, June 17, 8:54 AM BofA cuts its recommendation on Novo Nordisk (NVO -2.35%) to "neutral" from "buy" on concerns that data that Eli Lilly (LLY) is due to present at a conference later this week will show that the latter's dulaglutide diabetes treatment is better than Novo's Victoza. Novo investors are also worried about Sanofi's (SNY +2.4%) Lantus and a combination of the product with another drug called Lyxumia. Sanofi is scheduled to present at the conference as well but Novo is not. Comment! [Healthcare]
Monday, June 10, 9:33 AM Sanofi (SNY +0.1%) hopes the European Medicines Agency will give the green light to the company's Lemtrada treatment for multiple sclerosis this month. Lemtrada has been in development for 25 years and has had several different owners. It's already used for B-cell chronic lymphocytic leukaemia, but its patents are due to run out over the next few years. However, if Sanofi can get the IP protection extended and overcome safety concerns, it could make $700M-$1B a year from Lemtrada. 3 Comments [Healthcare]
Friday, June 7, 1:24 PM Jefferies is out with some price target revisions and color after conducting a "global pharma review." Rundown: Top U.S. pick Abbott Laboratories (ABT +1.9%) reiterated at Buy, PT lowered to $44 from $46; top global pick Novartis (NVS +0.3%) has "positive growth inflection potential" in FY14; AbbVie (ABBV +0.6%), Roche (RHHBY.OB +2.5%), and Sanofi (SNY +0.5%) offer "attractive entry points" but ABBV's PT is lowered to $51 from $54; Johnson & Johnson's (JNJ +0.2%) PT lowered to $91 from $97; Merck (MRK -0.3%) has its price target raised to $56 from $54 and Pfizer (PFE +1.3%) has its target lowered slightly to $32. (Previous: Jefferies SOTP analysis) 3 Comments [Healthcare, On the Move]
Monday, June 3, 4:34 AM Sanofi (SNY) will take a $285M charge on its H1 income after saying that it will halt the development of its iniparib drug after it failed in Phase III testing for lung cancer and a Phase II study for ovarian tumors. Sanofi acquired the drug in its $500M acquisition of BiPar Sciences in 2009. Sanofi has also halted the development of its anti-coagulant otamixaban after a poor Phase III trial. Shares are -2.1% in Paris. (PR) Comment! [Healthcare, On the Move, Top Stories]
Sunday, June 2, 3:57 AM Bristol-Myers Squibb's (BMY) immunotheapy nivolumab helped melanoma patients live an average of nearly 17 months in an early stage trial. While the study didn't have a comparator element, the duration of the survival exceeded historical norms for this form of skin cancer. In another trial, 68.9% of melanoma patients who took BMY's Yervoy together with Sanofi's (SNY) Leukine were alive a year later vs 52.9% of those who received just Yervoy. The findings were presented at the annual meeting of the American Society of Clinical Oncology. 3 Comments [Healthcare]
Friday, May 31, 8:16 AM The EMA's Committee for Medicinal Products for Human Use (CHMP) gives its blessing to Celgene's (CELG) oral multiple myeloma treatment pomalidomide based on data from a Phase 3 trial. The committee also adopts a positive opinion for Aegerion's (AEGR) HoFH treatment LOJUXTA and says new data does not support the contention that Sanofi's (SNY) Lantus increases the risk of cancer. AEGR + 0.92% premarket. Comment! [Healthcare]
Friday, May 31, 5:43 AM A dispute is taking place within the FDA over whether a class of blockbuster cardiovascular drugs called angiotensin receptor blockers ((ARBs)) significantly increase the risk of cancer. On one side is Thomas Marciniak, who believes they do, and on the other are his bosses, who think the medicines are safe. Companies that make ARBs, which generated $7.6B in U.S. sales last year, include Novartis (NVS), Merck (MRK), Sanofi (SNY), Bristol-Myers Squibb (BMY) and AstraZeneca (AZN). Comment! [Healthcare, Top Stories]
Wednesday, May 15, 3:10 PM Regeneron Pharmaceuticals (REGN -3.2%) and Sanofi (SNY -0.7%) have enrolled the first patients for trials of sarilumab, an injection to treat moderate-to-severe rheumatoid arthritis patients who are inadequate responders to either methotrexate or tumor necrosis factor alpha inhibitor therapy. Comment! [Healthcare, Global & FX]
Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
Thursday, May 2, 5:52 AM Sanofi (SNY) Q1 business net income falls to €1.61B (-12% Y/Y), or €1.22 per share, missing estimates . Revenue falls to €8.1B, missing by €200M . Results reflect the expiration of patents on Plavix and Eloxatin as well as U.S. generic competition for Avapro. All told, generic competition cost the firm more than half a billion euros in the quarter. The company also appoints two new executive committee members. Comment! [Earnings, Healthcare]
Wednesday, May 1, 10:36 AM Goldman raises its price target on Regeneron Pharmaceuticals (REGN +3%) to $240 from $230 after a survey of 41 U.S.-based cardiologists/lipidologists shows awareness of anti-PCSK9 drugs is widespread and "physicians project to use this class of drugs in 25-50% of their patients one year after approval." Putting it all together, Goldman hikes its peak sales estimates for REGN727 (developed with Sanofi SNY) to $3.5B from $3B and says it expects the company to report Phase III data in Q3. (Previoulsly: GS reiterates Buy on REGN) Comment! [Healthcare, On the Move]
Thursday, April 25, 9:30 AM Genzyme's (SNY -0.9%) Aubagio once-daily oral drug delayed the onset of multiple sclerosis in a study of patients who have experienced an attack of "clinically isolated syndrome," which is often a prelude to MS. Aubagio is already approved in the U.S., Australia and Argentina for treating relapsing forms of MS. (PR) Comment! [Healthcare]
Tuesday, April 23, 9:58 AM Sanofi (SNY) +2.5%) and its partner KaloBios Pharmaceuticals (KBIO) +5%) say the FDA has granted fast-track designation for the investigation of KB001A, an antibody fragment intended for protection against bacterial pneumonia caused by Pseudomonas aeruginosa in mechanically-ventilated patients. Under the partnership arrangement SNY is responsible for all clinical development, and is currently conducting a Phase I trial of the monoclonal antibody in the U.S. and has started Phase IIb planning. Comment! [Healthcare, On the Move]
Tuesday, April 2, 3:48 AM Sanofi (SNY) plans to continue expanding in China as it looks to generate double-digit sales growth in the country over the next five years. The French company intends to add four factories to six existing plants in order to boost production of pharmaceuticals, vaccines, and consumer health-care and animal-care products. Sanofi is also on the lookout for acquisitions. Comment! [Healthcare]
Wednesday, March 27, 1:02 PM The insulin war heats up, as Sanofi (SNY -0.9%) loses a key pitchman to archrival Novo Nordisk (NOVOB.PK). Former professional cyclist Phil Southerland, a diabetic whose team was funded by SNY for the past six years, has jumped ship along with his crew, now calling themselves Team Novo Nordisk. The stakes in this battle are big, as the global diabetes drug market right now runs at around $35B and continues to climb. At present, SNY dominates the market with Lantus, but its patent expires in 2015, and NOVOB - despite recent setbacks - continues to draft close behind. 1 Comment [Healthcare, On the Move, Global & FX]
Monday, March 25, 4:31 PM Sanofi (SNY -1.4%) says it's signed a collaboration agreement with Transgene SA to create a new industrial platform that will produce immunotherapy products including Transgene's therapeutic products. The platform will be established on Genzyme Polyclonals site, costing around €10M from both partners. The platform will remain Sanofi's exclusive property, and under the agreement, SNY's Genzyme will act as contract manufacturer. Comment! [Healthcare]

Dividend Sheet
$PVR $LINE and $APL are next Monday's best yielding ex-dividend stocks - http://stks.co/tB0i - 39 shares with 3.98% yield $SNY $CAKE
May 3, 2:11 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

mitrado
$SNY misses estimates... goes up 3.03%. Nice logic.
May 2, 10:57 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Chris DeMuth Jr.
MS Drug Lemtrada, owned by Sanofi ($SNY), Effective in Extension Trial: http://seekingalpha.com/a/nhht http://bloom.bg/WOVRiR
Mar 21, 5:42 PM
Reply (12)

• !Report Abuse
View all 12 replies
Landon R: I have not read, but happy to hear plans reach to 2022. http://on.wsj.com/10qu74z
May 15, 2:09 PM
• !Report Abuse
Landon R: Reaching for something as I see the price continue to drop. Tempted to go deeper.
May 15, 3:56 PM
• !Report Abuse
Add a reply...

140 characters

Dividend Sheet
$CHKR $EFC and $NRF are the best yielding stocks with recent dividend hikes from last week - http://stks.co/gM5z - I like $SNY and $CMCSA
Feb 17, 8:22 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$NGG $SNY and $CS are the best yielding stocks with buy or better rating from Europe + http://stks.co/eJcR + I like $NVO $BUD and $COV
Jan 31, 4:21 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Closet Iguana
Healthcare Cloud Computing Market is Expected to Reach USD 6.7B http://adf.ly/HsEQB $SNY $EMR $AMGN $GILD
Jan 24, 2:22 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Dividend Sheet
$HLF $SNY and $COV are the best yielding stocks from the top 20 buy rated healthcare stocks + http://stks.co/cHAs + I also like $NVO $COO
Jan 2, 4:06 AM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Thursday - $TROV, $ONTY, $PBTH, $C, $UBS, $DNDN, $TEVA, $SIRI, $LMCA, $JPM, $MDVN, $SNY, http://bit.ly/cAHZ42
12/20/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Hawkbill54
$SNY What would be a good entry point for buying? 40?
12/8/12
Reply (3)

• !Report Abuse
View all 3 replies
joe kelly: $40 would be a real good entry for SNY. Be a while for it goes down that far..
12/9/12
• !Report Abuse
chopchop0: It's been on a tear the last few months. Wish I had bought more in the 30s. It's popping after hours now to new highs.
Jan 7, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
Stocks breaking out today on heavier than normal volume: APP, EGHT, FDS, HOV, SPNC, SNY, TRV.
9/11/12
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: APP, EGHT, HOV, SPNC less than $15/share.
9/11/12
• !Report Abuse
Ocean Man: Go APP, let's see a short squeeze. 12% short and 17 days to cover.
9/12/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

Chris DeMuth Jr.
MS Drug Lemtrada, owned by Sanofi ($SNY), Effective in Extension Trial: http://seekingalpha.com/a/nhht http://bloom.bg/WOVRiR
Mar 21, 5:42 PM
Reply (12)

• !Report Abuse
View all 12 replies
Landon R: I have not read, but happy to hear plans reach to 2022. http://on.wsj.com/10qu74z
May 15, 2:09 PM
• !Report Abuse
Landon R: Reaching for something as I see the price continue to drop. Tempted to go deeper.
May 15, 3:56 PM
• !Report Abuse
Add a reply...

140 characters

greengirl64
Anyone know why Sanofi (SNY) opened lower today?
1/4/12
Reply (4)

• !Report Abuse
View all 4 replies
Ocean Man: Nice run from 32 to 37. Big dividend increase coming in May.
1/4/12
• !Report Abuse
Desperado2012: 4Q2012 results!
Feb 7, 6:01 AM
• !Report Abuse
Add a reply...

140 characters

Hawkbill54
$SNY What would be a good entry point for buying? 40?
12/8/12
Reply (3)

• !Report Abuse
View all 3 replies
joe kelly: $40 would be a real good entry for SNY. Be a while for it goes down that far..
12/9/12
• !Report Abuse
chopchop0: It's been on a tear the last few months. Wish I had bought more in the 30s. It's popping after hours now to new highs.
Jan 7, 4:17 PM
• !Report Abuse
Add a reply...

140 characters

Dr. Kris
Stocks breaking out today on heavier than normal volume: APP, EGHT, FDS, HOV, SPNC, SNY, TRV.
9/11/12
Reply (2)

• !Report Abuse
View all 2 replies
Dr. Kris: APP, EGHT, HOV, SPNC less than $15/share.
9/11/12
• !Report Abuse
Ocean Man: Go APP, let's see a short squeeze. 12% short and 17 days to cover.
9/12/12
• !Report Abuse
Add a reply...

140 characters

jdub2788
SNY, wow. I had this from $33 in my other IRA. Totally forgot about it. Selling here for 22%ish in 7 months.
8/22/12
Reply (3)

• !Report Abuse
View all 3 replies
Hillbilly Stock Star: PRWCX......for IRA, so far so good.
8/22/12
• !Report Abuse
joe kelly: SNY is the only stock I am truly long. Similar cash positions to yours Jdub
8/22/12
• !Report Abuse
Add a reply...

140 characters

The_American
TC holding at these levels even on the EUO dip. Great companies TEF FTE SNY pay SDIV HDGE XLF BAC JPM MS BCS : GLD SLV accumulation FXI YINN
7/24/12
Reply (1)

• !Report Abuse
View all 1 replies
Garthilk: TEF is going to 7 dollars. The 2011 3:1 split, the share price was in the 20 range, add in Euro crisis, Spain falling apart.
7/24/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
MO and RAI getting attractive. Also watching IBM, CLR, SNY, and NES.
1/6/12
Reply (2)

• !Report Abuse
View all 2 replies
kenjotto: I've owned NES for about 8 months. That guy is going to do great things for stockholders
1/6/12
• !Report Abuse
Ocean Man: I'm in with you now.
1/6/12
• !Report Abuse
Add a reply...

140 characters

Ocean Man
Sold ELRC today for a 4% gain in 2 days. Sold some of my LYB, SNY, and NVS. LYB was up a bit, other 2 about where I bought them.
11/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Ocean Man: LYB had insider buys of $60M last week and another $30M this week, but the combo of European and chemical co scares me too much.
11/29/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Looking to add some Pharma tomorrow on a down move..Long PG PRU APA DD EMC SBUX...ABT SNY CELG GILD NVO on watch.
11/29/11
Reply (1)

• !Report Abuse
View all 1 replies
Chines33: I have just covered my silver short in AGQ for a .50 gain.
11/29/11
• !Report Abuse
Add a reply...

140 characters

Chines33
UN SNY AXP PG PRU KO SLB all on my list to add on another day like this
11/23/11
Reply (11)

• !Report Abuse
View all 11 replies
1980XLS: Tuna, NEVER buy AA, unless for a quick daytrade. NEVER!
11/23/11
• !Report Abuse
Ocean Man: I added T yesterday and NVS today. Some stocks are hitting or nearing their 52-week lows before others. Almost added TEF and AT, maybe Fri.
11/23/11
• !Report Abuse
Add a reply...

140 characters

Chines33
No new debt cuts cut releave downward pressure on healthcare that typically outperforms in bear markets long SNY eying ABT NVO BMY
11/21/11
Reply (19)

• !Report Abuse
View all 19 replies
TruffelPig: Actually, about 50% because I have money markets ongoing that I won't touch.
11/21/11
• !Report Abuse
edje: Chines, what is your year end target?
11/21/11
• !Report Abuse
Add a reply...

140 characters

Chines33
PG SNY lone bright spots on my board.
11/17/11
Reply (1)

• !Report Abuse
View all 1 replies
vinyal: It's all over folks
11/17/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Out of HES 63.68 modest gain..Long APA ESV SLB FLR BHP EMC BRCM PRU JCI DD ETN PG SBUX TJX SNY
11/16/11
Reply (3)

• !Report Abuse
View all 3 replies
Chines33: Oops also long WY
11/16/11
• !Report Abuse
Chines33: Actually added to it earlier as posted
11/16/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Long PRU PG EMC BRCM APA ESV BHP FLR JCI DD ETN WY SNY TJX SBUX
11/15/11
Reply (9)

• !Report Abuse
View all 9 replies
Chines33: Lol I know you are joking but just clarifying for others.
11/15/11
• !Report Abuse
Clayton Rulli: SBUX is truely on FIREEEEE
11/15/11
• !Report Abuse
Add a reply...

140 characters

Chines33
Still long PRU APA ESV FLR BHP WY DD ETN JCI PG SNY TJX SBUX EMC BRCM..had some very nice day trades in HES and GS sold out of JOY
11/15/11
Reply (1)

• !Report Abuse
View all 1 replies
sstonerm3: Chines, since no one (shorts) is calling you out today, let me be the first. Congratulations on a good day's work.
11/15/11
• !Report Abuse
Add a reply...

140 characters

SNY sanofi-aventis

SNY

sanofi-aventis